

# SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

Of

# **DE SHALOM VITAMIN C SYRUP**

#### 1. NAME OF THE MEDICINAL PRODUCT

De-Shalom Vitamin C Syrup

# 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5ml contains:

For a full list of Excipients, See Section 6.1

#### 3. PHARMACEUTICAL FORM

Oral Liquid Syrup. Orange clear syrupy liquid.

#### 4. CLINICAL PARTICULARS

# 4.1 Therapeutics indications

De-Shalom Vitamin C is used in the prevention and treatment of Vitamin C deficiency. De-Shalom Vitamin C is used for prevention and treatment of scurvy. It assists in the healing of wounds and prevention of body infection. De-Shalom Vitamin C is essential for the maintenance of good health in infants and children

#### 4.2 Posology and method of administration

For Oral use.

De-Shalom Vitamin C contains Ascorbic Acid (Vitamin C) – a water-soluble vitamin, which is essential for the maintenance of healthy growth. Deficiency in the intake of Vitamin C leads to scurvy which is characterized by capillary fragility and bleeding (especially from the gum), anaemia, cartilage/bone lesion and slow healing of wounds.

#### Method of administration

Children: Half to one 5ml teaspoonful daily.

Adults and children and above 10 years: One to two 5ml teaspoonful daily.

#### 4.3 Contraindications

De-Shalom Vitamin C Syrup should not be used in, oxalate-urolithiasis and iron storage diseases (thalassaemia, haemochromatosis, sideroblastic anaemia).

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

# 4.4 Special warnings and precautions for use

Care should be taken in giving De-Shalom Vitamin C to patient with hyperoxaluria as this may alter the excretion of certain other drugs administered concurrently.

Increased intake of ascorbic acid over a prolonged period may result in an increase in renal clearance of ascorbic acid and deficiency may result, if it is withdrawn.

For patients with extreme or terminal renal insufficiency (patients of dialysis), respectively, a daily vitamin-C-uptake of 50 to 100 mg of vitamin C should not be exceeded, because otherwise, there is the risk of hyperoxalataemia and crystallisations of oxalate in the kidneys. High dose vitamin C therapy should be avoided in patients with underlying renal insufficiency or urinary oxalate should be monitored in patients. Nephrotoxic symptoms can occur in patients with renal failure and patients who concomitantly use medicinal products with negative effect on the renal function, e.g. iron overload due to enhanced iron reabsorption.

## 4.5 Interaction with other medicinal products and other forms of interaction

Corticosteroids increase the oxidation of ascorbic acid. Calcitonin increases the rate of vitamin C consumption. Salicylates inhibit active transportation through the intestine. Tetracyclines inhibit intracellular metabolism and reabsorption from the renal tubes. Acetylsalicylic acid, barbiturates and tetracyclines increase vitamin C excretion in the urine.

Several cases have been reported, in which ascorbic acid appeared to reduce the effect of warfarin.

Ascorbic acid can decrease the therapeutic effect of phenothiazines. The concentration of fluphenazine may also be reduced

High doses of vitamin C taken together with iron may cause an iron overload due to enhanced iron reabsorption.

High doses of vitamin C taken together with aluminum may cause increased aluminum reabsorption.

Chronic use of high doses of ascorbic acid may interfere with disulfiram – alcohol interaction when used concurrently. Alcohol reduces ascorbic acid levels.

#### 4.6 Fertility, pregnancy and lactation

#### Pregnancy

It is not advisable to exceed the given dosage during pregnancy and lactation. There is limited amount of data from the use of high dose vitamin C in pregnant women. It is not clear if vitamin C supplementation in amounts exceeding Dietary Reference Intake recommendations is safe or beneficial.

**Breastfeeding** 

Ascorbic acid is secreted into breast milk and crosses the placental barrier by means of simple

diffusion. There is insufficient information on the effects of high dose vitamin C in newborns/

infants. It is not clear if vitamin C supplementation in amounts exceeding Dietary Reference

Intake recommendations is safe or beneficial.

**Fertility** 

The effect of large doses on the fetus is not known.

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

Respiratory and cutaneous hypersensitivity reactions have been observed in isolated cases.

4.9 Overdose

De-Shalom Vitamin C (Vitamin C) is usually well tolerated. Large doses are reported to

cause diarrhoea and other gastro-intestinal disturbance and are associated with the formation

of renal calcium oxalate calculi. Patients with recurring formation of renal calculi are

recommended not to exceed a daily vitamin-C-uptake of 100 to 200 mg.

5 PHARMACOLOGICAL PROPERTIES

**5.1 Pharmacodynamic properties** 

Pharmacotherapeutic group: Ascorbic acid (vitamin C)

ATC-Code: A11GA01

Vitamin C is essential to humans. Its components, ascorbic acid andehydroascorbic acid, form

an important redox system.

Vitamin C acts as a cofactor in numerous enzyme systems due to its redox potential (collagen

formation, catecholamine synthesis, hydroxylation of steroids, tyrosine and exogenous

substances, biosynthesis of carnitin, regeneration of tetrahydrofolic acid and alpha-amidisation

of peptides, e.g. ACTH and gastrin).

Further, a deficiency of vitamin C affects the immune defence reactions, particularly

chemotaxis, complement activation and interferon production. The molecular biological

functions of vitamin C have not yet been fully explained.

Ascorbic acid improves the re-absorption of iron salts by reducing ferric ions and by forming

iron chelates. It blocks the chain reactions in aqueous body compartments triggered by oxygen

radicals.

The antioxidative functions produce biochemical interactions in close relation to those of vitamin E, vitamin A and carotinoids. As yet it has not been proven entirely that ascorbic acid causes a reduction of potentially carcinogenic substances in the gastrointestinal tract.

# **5.2 Pharmacokinetic properties**

Ascorbic acid is absorbed in the proximal small intestine in a dose-dependent manner. The bioavailability drops with increasing dosage to 60 - 75% after 1 g, to approx. 40% after 3 g and approx. 16% after 12 g. The portion which is not absorbed is broken down by the large intestinal flora into CO<sub>2</sub> and organic acids.

The maximal metabolic turnover of 40 to 50 mg/day in healthy adults is reached at plasma concentrations of 0.8 to 1.0 mg/dl. The total daily turnover is about 1 mg/kg BW. Brief plasma concentrations of up to 4.2 mg/dl are achieved about three hours after applying extremely high oral doses.

Under these circumstances ascorbic acid is eliminated in the urine by up to 80%. The half-life constitutes 2.9 hours on average. Renal elimination ensues via glomerular filtration and subsequent reabsorption in the proximal tubule.

The total body content of ascorbic acid is at least 1.5 g following a high dose of about 180 mg daily. Ascorbic acid is concentrated in the pituitary gland, adrenal glands, lenses of the eye and white blood cells.

#### 5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on studies of single and repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

#### 6 PHARMACEUTICAL PARTICULARS

#### **6.1** List of excipients

- Sodium Metabisulphite
- Sodium Carbonate
- Sodium Chloride
- EDTA
- Dextrose Powder
- CMC
- Methyl Paraben

- Propyl Paraben
- Sucrose
- Glycerine
- Ethanol
- Pineapple Flavour
- Sunset Yellow

# **6.2** Incompatibilities

None known

#### 6.3 Shelf life

18 months.

# 6.4 Special precautions for storage

Store below 30 °C. Keep away from sunlight.

Keep out of reach of children.

#### 6.5 Nature and contents of container

100ml amber bottle in a cardboard carton

# 6.6 Special precautions for disposal and other handling

No special requirements apart from NAFDAC guidelines

## 7 MARKETING AUTHORISATION HOLDER

DE-SHALOM PHARM LAB NIG. LTD.

Km 4, Iloko-Ijesa Road, Ilesa, Osun-State, Nigeria.

Phone:08034088756

Email: deshalompharm@gmail.com